Genetic Polymorphisms of the UDP-Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients

Maki Ando, Yuichi Ando, Yoshitaka Sekido, Masahiko Ando, Kaoru Shimokata and Yoshinori Hasegawa

First Department of Internal Medicine, Department of Clinical Preventive Medicine and Department of Preventive Medicine/Biostatistics and Medical Decision Making, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550

Irinotecan often causes unpredictably severe, occasionally fatal, toxicity involving leukopenia or diarrhea. It is converted by carboxyesterase to an active metabolite, SN-38, which is further conjugated and detoxified to SN-38-glucuronide by UDP-glucuronosyltransferase (UGT). We genotyped the UGT1A7 gene by direct sequencing analysis and polymerase chain reaction-restriction fragment length polymorphism in 118 cancer patients and 108 healthy subjects. All the patients had received irinotecan-containing chemotherapy and were evaluated to see whether the variant UGT1A7 genotype would increase the likelihood of severe toxicity of irinotecan consisting of grade 4 leukopenia and/or grade 3 or more diarrhea. Among the 26 patients with severe toxicity, the allele frequencies were 61.5% for UGT1A7*1, 15.4% for UGT1A7*2, and 23.1% for UGT1A7*3. On the other hand, the frequencies were 63.6% for UGT1A7*1, 15.8% for UGT1A7*2, and 20.7% for UGT1A7*3 among the 92 patients without severe toxicity. None of the 118 patients had UGT1A7*4.

Neither univariate analysis (odds ratio, 1.13; 95% confidential interval, 0.46–2.75) nor multivariate logistic regression analysis (odds ratio, 0.74; 95% confidential interval, 0.26–2.07) found any significant association between carrying at least one of the variant alleles and the occurrence of severe toxicity. The distribution of UGT1A7 genotypes in 108 healthy subjects was not significantly different from that in the patients (P=0.99 and 0.86 for those with and without severe toxicity, respectively), but significantly less than that in Caucasians reported previously (P<<0.001). The results suggested that determination of UGT1A7 genotypes would not be useful for predicting severe toxicity of irinotecan.

Key words: UDP-glucuronosyltransferase 1A7 — Irinotecan — SN-38 — Genetic polymorphisms

Irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, CPT-11) is a camptothecin analogue with strong antitumor activity that inhibits topoisomerase I, which is now commonly used in the treatment of patients with colorectal or lung cancers. Irinotecan is hydrolyzed by carboxylesterase to form SN-38 (7-ethyl-10-hydroxycamptothecin), which has a 100- to 1000-fold higher antitumor activity than the parent drug. SN-38 is conjugated by UDP-glucuronosyltransferase (UGT) 1A1 in the liver to yield SN-38 glucuronide, which has 1/100 the antitumor activity of SN-38. SN-38 glucuronide is excreted in the small intestine via bile, where bacterial glucuronidase resolves the glucuronide into SN-38 and glucuronic acid. A part of the SN-38 is reabsorbed from the intestine into body, resulting in enterohepatic circulation of SN-38.

Irinotecan often causes unpredictably severe, occasionally fatal, toxicity involving leukopenia or diarrhea. An inter-individual difference in drug sensitivity would be caused by a difference in drug disposition after irinotecan administration. We have recently suggested that genetic polymorphisms of UGT1A1 could explain some of the inter-individual differences in the pharmacokinetics and pharmacodynamics of irinotecan. The metabolic ratios (SN-38/SN-38 glucuronide) in a patient homozygous for UGT1A1*28, having a 2-base pair (bp) insertion (TA) in the TATA box in the promoter region, were uncharacteristically higher than those in other patients. Furthermore, a case control study of 118 Japanese patients, who had received irinotecan for cancer, revealed that genotypes either heterozygous or homozygous for UGT1A1*28 would be a significant risk factor for severe irinotecan toxicity. Thus, we considered that patients with variant genotypes of the UGT1A1 gene would be at higher risk for severe toxicity due to a relatively increased bioavailability of active unconjugated SN-38.

Besides UGT1A1, another UGT isoform, UGT1A7, has been recently reported to glucuronidate SN-38 at a more than 9-fold higher level than that by UGT1A1 in vitro, using the human UGT1 enzymes expressed transiently in COS-1 cells. UGT1A7 is expressed in the gastrointestinal and lung, but not in the liver. Since it has been

To whom correspondence and reprints requests should be addressed.
E-mail: yhasega@med.nagoya-u.ac.jp
reported that SN-38 concentrations in intestinal tissues, as well as in liver, were high after irinotecan administration, it can be speculated that SN-38 is conjugated to SN-38 glucuronide again by UGT1A7 after reabsorption into the intestinal tissues. Furthermore, an inverse relationship between SN-38 glucuronidation and diarrhea was reported in cancer patients treated with irinotecan. In mouse models, a dose-dependent relationship between diarrhea and accumulation of SN-38 in the intestine has been noted after intraperitoneal administration of irinotecan. Thus, we hypothesized that the UGT1A7 polymorphisms would also affect the occurrence of severe toxicity by irinotecan, especially in respect to diarrhea, through modifying the enzyme activity in gastrointestinal tissues. Single nucleotide polymorphisms (SNPs) of the UGT1A7 gene are known to be linked to the in vitro enzymatic activity: UGT1A7*1 (N129R 131W 208 as the reference sequence), UGT1A7*2 (K 129K 131W 208), UGT1A7*3 (K129K 131R 208), and UGT1A7*4 (N129R 131R 208). UGT1A7*2 comprises two transversions and one transition (T387G, C391A and G392A), which produce the amino acid substitutions Asn129Lys and Arg131Lys, respectively. UGT1A7*3 comprises two transversions and two transitions (T387G, C391A, G392A and T622C), producing Asn129Lys, Arg131Lys and Trp208Arg, respectively. UGT1A7*4 has a T622C transition producing a Trp208Arg substitution. When these four UGT1A7 variants were expressed in HEK cells and their in vitro enzymatic activities toward benzo(α)pyrene metabolites were examined, the membrane from the UGT1A7*3-expressing cells exhibited a 5.8-fold lower relative Vmax compared to that of UGT1A7*1, whereas UGT1A7*2 and UGT1A7*4 had a 2.6- and 2.8-fold lower relative Vmax than UGT1A7*1, respectively. While the previous population study revealed that more than 85% of Caucasians had at least one of the three variant alleles, the frequency of UGT1A7 allele in Asians has not yet been reported. We hypothesized that UGT1A7 polymorphisms would also affect inter-patient or inter-ethnic variations in sensitivity to drugs or carcinogens.

The purpose of this study is to evaluate the influence of genetic polymorphisms of UGT1A7 gene on risk for severe irinotecan toxicity in cancer patients treated with irinotecan, as well as the frequency of the UGT1A7 allele in the healthy Japanese population.

MATERIALS AND METHODS

Subjects We genotyped the UGT1A7 gene in 118 cancer patients and 108 healthy subjects (31 females and 77 males; median age 49 years). We retrospectively reviewed the clinical records including patient characteristics (age, Table I. Baseline Characteristics of Patients

| Leukopenia (grade 4) and/or diarrhea (grade 3 or worse) | Experienced (N=26) | Not experienced (N=92) | P |
|-------------------------------------------------------|-------------------|------------------------|---|
| Gender (men/women)                                    | 14/12             | 66/26                  | 0.085<sup>a</sup> |
| Median age (range, years)                             | 60 (38–76)        | 61 (41–75)             | >0.2<sup>b</sup> |
| Performance status                                    |                   |                        | >0.2<sup>b</sup> |
| 0                                                     | 8 (31%)           | 31 (34%)               | >0.2<sup>b</sup> |
| 1                                                     | 15 (58%)          | 51 (55%)               | >0.2<sup>b</sup> |
| ≥2                                                    | 3 (12%)           | 10 (11%)               | >0.2<sup>b</sup> |
| Primary disease                                       |                   |                        | >0.2<sup>b</sup> |
| Small cell lung                                       | 4 (15%)           | 17 (18%)               | >0.2<sup>b</sup> |
| Non-small cell lung                                   | 16 (62%)          | 49 (53%)               | >0.2<sup>b</sup> |
| Colorectal                                            | 3 (12%)           | 18 (20%)               | >0.2<sup>b</sup> |
| Other                                                 | 3 (12%)           | 8 (9%)                 | >0.2<sup>b</sup> |
| Distant metastases                                    | 21 (81%)          | 68 (74%)               | >0.2<sup>b</sup> |
| Previous treatment                                    |                   |                        | >0.2<sup>b</sup> |
| None                                                  | 12 (46%)          | 36 (39%)               | >0.2<sup>b</sup> |
| Systemic chemotherapy                                 | 12 (46%)          | 47 (51%)               | >0.2<sup>b</sup> |
| Surgery                                               | 8 (31%)           | 34 (37%)               | >0.2<sup>b</sup> |
| Radiotherapy                                          | 3 (12%)           | 17 (18%)               | >0.2<sup>b</sup> |
| Complications                                         |                   |                        | >0.2<sup>b</sup> |
| Diabetes                                              | 2 (8%)            | 8 (9%)                 | >0.2<sup>b</sup> |
| Liver diseases                                        | 3 (12%)           | 6 (7%)                 | >0.2<sup>b</sup> |

<sup>a</sup> Japan Society for Cancer Therapy criteria.<br><sup>b</sup> χ² test.<br><sup>c</sup> Mann-Whitney U test.
gender, primary disease, previous treatments, evidence of distant metastasis, Eastern Cooperative Oncology Group performance status, and major complications), dosage and schedule of irinotecan administration, concurrent use of other drugs or radiotherapy, and observed toxicity following irinotecan infusion (Tables I and II). The chemotherapy regimens were categorized into 3 groups; irinotecan alone, irinotecan plus platinum (cisplatin or carboplatin), and irinotecan plus other agents (paclitaxel, docetaxel, etoposide, mitomycin C or 5-fluorouracil). We counted the number of days when patients received granulocyte colony stimulating factors or loperamide hydrochloride, which is commonly prescribed for irinotecan-induced diarrhea in Japan. Prophylactic uses of granulocyte colony stimulating factor could not be clearly distinguished from those for neutropenia. Since the dose-limiting toxicity of irinotecan results in leukopenia and diarrhea,2) we defined “severe toxicity” in this research as leukopenia of grade 4 (<0.9×10^9/liter) and/or diarrhea of grade 3 or worse (grade 3, watery for 5 days or more; grade 4, hemorrhagic or dehydration), classified in accordance with the Japan Society for Cancer Therapy criteria.17) Then, we identified 26 patients who had experienced severe toxicity and 92 patients who did not. All the patients gave informed consent in writing for their peripheral blood to be used for the research. All healthy subjects, who were unrelated and were not found to have any malignant diseases by medical checkup at Nagoya University Hospital, were consecutively enrolled after having given their informed consent in writing for their blood to be used in the genetic research. The study was approved by the Ethical Committees of Nagoya University School of Medicine and the participating institutes.

Table II. Information on Irinotecan Chemotherapy

| Regimens                  | Experienced (N=26) | Not experienced (N=92) | P     |
|---------------------------|-------------------|-----------------------|-------|
| Regimens                  |                   |                       |       |
| Irinotecan alone          | 3 (12%)           | 32 (35%)              | 0.015 |
| Irinotecan & platinum     | 13 (50%)          | 45 (49%)              |       |
| Irinotecan & other        | 10 (38%)          | 15 (16%)              |       |
| Concurrent radiotherapy   | 1 (4%)            | 8 (9%)                | >0.2  |
| Intended schedule         |                   |                       |       |
| Weekly (days 1, 8 and 15) | 15 (72%)          | 62 (67%)              | 0.059 |
| Every 3 or 4 weeks        | 8 (31%)           | 11 (12%)              |       |
| Twice every 4 weeks       | 3 (12%)           | 19 (21%)              |       |
| Intended irinotecan dosage for each infusion (mg/m^2) | >0.2  |
| <60                       | 9 (35%)           | 18 (20%)              |       |
| 60                        | 8 (31%)           | 34 (37%)              |       |
| >60                       | 9 (35%)           | 40 (43%)              |       |
| Total actual dosage (mg/m^2) |                   |                       | 0.010 |
| <300                      | 15 (58%)          | 24 (26%)              |       |
| 301–600                   | 7 (27%)           | 46 (50%)              |       |
| >600                      | 4 (15%)           | 22 (24%)              |       |
| Use of granulocyte colony-stimulating factor (days) | <0.001 |
| 0                         | 5 (19%)           | 61 (66%)              |       |
| 1–14                      | 11 (42%)          | 13 (14%)              |       |
| ≥15                       | 10 (38%)          | 18 (20%)              |       |
| Use of loperamide hydrochloride (days) | 0.002 |
| 0                         | 4 (15%)           | 51 (55%)              |       |
| 1–7                       | 15 (58%)          | 28 (30%)              |       |
| ≥8                        | 7 (27%)           | 13 (14%)              |       |

a) Japan Society for Cancer Therapy criteria.
b) χ^2 test.
c) Fisher’s exact test.

Genotyping Genomic DNA was prepared from whole blood (100–200 µl) using a QIAamp Blood Kit (QIAGEN GmbH, Hilden, Germany). We distinguished the following variant UGT1A7 alleles from the reference allele UGT1A7*1 by direct sequencing analyses: UGT1A7*2,
**RESULTS**

Among the 26 patients with severe toxicity, the allele frequencies were 61.5% for UGT1A7*1, 15.4% for UGT1A7*2, and 23.1% for UGT1A7*3. On the other hand, 63.6% for UGT1A7*1, 15.8% for UGT1A7*2, and 20.7% for UGT1A7*3 were found among the 92 patients without severe toxicity. None had UGT1A7*4 among the total of 118 patients. Distributions of UGT1A7 genotypes among the patients who experienced severe toxicity and those who did not were apparently comparable (Table III). Univariate analysis showed no significant association between carrying at least one of the variant alleles and the occurrence of severe toxicity (crude odds ratio, 1.13; 95% CI, 0.46–2.75). The relationship remained non-significant after controlling for the other factors (Table IV). Among the 26 patients with severe toxicity, 3 and 19 patients experienced grade 4 and grade 3 diarrhea, respectively, and there was no significant association between the variant alleles and the incidence of such diarrhea (crude odds ratio, 1.27; 95% CI, 0.50–3.46). Genotypes of the 3 individuals who experienced grade 4 diarrhea were UGT1A7*1/UGT1A7*3, UGT1A7*2/UGT1A7*3 and UGT1A7*3/UGT1A7*3.

The allelic frequencies in 108 healthy subjects were 59.2% for UGT1A7*1, 15.3% for UGT1A7*2 and 25.5% for UGT1A7*3. The UGT1A7*4 allele was not found in this healthy population. The patients heterozygous for the variant sequences at the three codons 129, 131 and 208 gave an undigested fragment (genotyped as UGT1A7*1/UGT1A7*3), whereas that from UGT1A7*2 and UGT1A7*3, with the same reverse primer used in the first PCR. One micro liter of the 1000-fold-diluted product of the first PCR was subjected to the hemi-nested PCR-restriction fragment length polymorphism (RFLP) assay was performed to determine the haplotype of these individuals. We used a forward primer 5′-GAGTCAGAAGTCATATGACCG-3′ (nucleotides 365 to 392), which matches UGT1A7*1 and UGT1A7*4 (reference sequence at codon 131), but not UGT1A7*2 and UGT1A7*3, with the same reverse primer used in the first PCR. One micro liter of the 1000-fold-diluted product of the first PCR was subjected to the hemi-nested PCR. The PCR condition was: 95°C for 5 min followed by 25 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 40 s (PCR Thermal Cycler MP, Takara Shuzo Co., Ltd.).

The possible genotypes for individuals heterozygous for the variant sequences at the three codons 129, 131 and 208 are UGT1A7*1/UGT1A7*3 or UGT1A7*2/UGT1A7*4. Hemi-nested PCR-restriction fragment length polymorphism (RFLP) assay was performed to determine the haplotype of these individuals. We used a forward primer 5′-GAGTCAGAAGTCATATGACCG-3′ (nucleotides 365 to 392), which matches UGT1A7*1 and UGT1A7*4 (reference sequence at codon 131), but not UGT1A7*2 and UGT1A7*3, with the same reverse primer used in the first PCR. One micro liter of the 1000-fold-diluted product of the first PCR was subjected to the hemi-nested PCR. The PCR condition was: 95°C for 5 min followed by 25 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 40 s. Only DNA from UGT1A7*1 or UGT1A7*4 gave a 454-bp fragment, which was subsequently digested with Rsal (Toyobo Co., Tokyo) for 1 h at 37°C. Restriction fragments were analyzed by 4% agarose gel electrophoresis and ethidium bromide staining. DNA from UGT1A7*1 gave an undigested fragment (genotyped as UGT1A7*1/UGT1A7*3), whereas that from UGT1A7*2 and UGT1A7*3 was digested into 256- and 198-bp fragments (genotyped as UGT1A7*2/UGT1A7*4).

Statistical analysis: The correlation or association between potential variables was assessed using the χ² test or Fisher’s exact test for categorical variables, or the Mann-Whitney U test for continuous ones. A crude odds ratio with a 95% confidence interval (CI) was calculated to analyze the association between carrying at least one of the variant UGT1A7 alleles and severe irinotecan toxicity. Multivariate logistic regression analysis was used to assess the association when controlling for other variables. Possible variables that seemed to be associated with severe toxicity (P<0.01) were evaluated by stepwise procedures to be included in the final model: UGT1A1*28, female gender, and chemotherapy regimen, which were recognized as important covariates to explain the severe toxicity in the previous study. We performed these analyses using SAS ver. 6.12 software (SAS Institute Inc., Cary, NC). A difference was considered statistically significant when the two-tailed P value was under 0.05.

| Toxicity | 1/1 | 1/2 | 1/3 | 2/2 | 2/3 | 3/3 |
|----------|-----|-----|-----|-----|-----|-----|
| Yes      | 26  | 38% | 15% | 31% | 4%  | 8%  | 4%  |
| No       | 92  | 41% | 21% | 24% | 3%  | 4%  | 7%  |

a) None had UGT1A7*4.
b) Leukopenia of grade 4 and/or diarrhea of grade 3 or worse (the Japan Society for Cancer Therapy criteria).
In the Japanese population, we did not find a significant association between the UGT1A7 genotypes and the severe leukopenia and/or diarrhea caused by irinotecan, though UGT1A7 has been reported to glucuronidate SN-38 more efficiently than UGT1A1 in vitro. The reason for this discrepancy is unclear, but it might be because UGT1A1 is expressed in the liver, the primary organ for detoxifying intravenous irinotecan, while UGT1A7 is not. This finding suggests that UGT1A7 would play only a minor role in SN-38 glucuronidation in vivo.

In addition, we found the variant UGT1A7 alleles are rare in the Japanese population compared with those reported in Caucasians. Additionally, the UGT1A7*4 allele, whose frequency in Caucasians has been reported as 0.017, has not been found in Japanese. This is the first report investigating inter-ethnic differences in the frequency of the variant UGT1A7 alleles. Such UGT1A7 polymorphisms are potentially a cause of inter-patient or inter-ethnic variations in sensitivity to drugs or carcinogens that are metabolized by UGT1A7.

Genetic polymorphisms of drug-metabolizing enzymes might also be an important factor in cancer susceptibility. So far, several phase I drug-metabolizing enzymes, such as cytochrome P450 (CYP1A1, CYP2D6 or CYP2E1), and phase II enzymes (N-acetyltransferase or glutathione S-transferase) have been reported to be associated with an increased risk of cancers. Glucuronidation by UGTs is regarded as an important pathway to detoxify toxic and/or carcinogenic compounds. Differences in the activities of these enzymes might cause variations in the toxic or carcinogenic effects of drugs or environmental pollutants. In an in vitro expression systems, the UGT1A7 polymorphisms exhibited significant variations in glucuronidation activity towards 3-, 7-, and 9-hydroxybenzo[a]pyrene, which is a strong carcinogen in cigarette smoke. On the other hand, the UGT1A-deficient Gunn rat was more susceptible to DNA adduct formation after exposure to benzo[a]pyrene than the UGT1A-intact rat. Significant associations of UGT1A7 genotypes with risks of hepatocellular or orolaryngeal cancers have recently been reported. Although the distributions of the UGT1A7 polymorphisms did not differ among cancer patients and the healthy subjects in this study, further investigation into the effects of polymorphism on cancer susceptibility is necessary. Since

---

**Table IV. Results of Multivariate Logistic Regression Analysis to Identify Predictors of Toxicity**

| Term               | β  | SE  | χ²  | P value | Odds ratio (95%CI) |
|--------------------|----|-----|-----|---------|-------------------|
| Intercept          | −3.047 | 0.695 |     |         |                   |
| UGT1A1*28          | 1.972 | 0.568 | 12.04 | 0.0005  | 7.18 (2.36–21.87)  |
| Regimen            | 1.234 | 0.505 | 5.97  | 0.0146  | 3.43 (1.28–9.24)   |
| Gender             | 0.917 | 0.513 | 3.19  | 0.0740  | 2.50 (0.92–6.84)   |
| UGT1A7*4           | −0.301 | 0.525 | 0.33  | 0.5661  | 0.74 (0.26–2.07)   |

a) β=coefficient.
b) UGT1A1*28 has a two-extra-nucleotide insertion (TA) within the TATA box, altering the sequence from (TA)₆TAA to (TA)₇TAA.
c) Regimen of irinotecan plus other anticancer drugs apart from platinums.
d) UGT1A7*1 apart from UGT1A7*2, UGT1A7*3, and UGT1A7*4.

---

**Table V. Genotypes of UGT1A7 in Healthy Japanese and Caucasian Populations**

| Variant | Japanese | Caucasians |
|---------|----------|------------|
|         | N (N=108) Frequency (%) (95%CI) | N (N=144) Frequency (%) (95%CI) |
| UGT1A7 genotypes | | Guillmette et al. |
| '1'/1 | 39 | 36.1% (27.1–45.9) | 21 | 14.6% (9.3–21.4) |
| '1'/2 | 19 | 17.6% (10.9–26.1) | 30 | 19.5% (14.5–28.4) |
| '1'/3 or '2'/4 | 31 | 28.7% (20.4–38.2) | 30 | 20.8% (14.5–28.4) |
| '1'/4 | 0 | 0% (0.0–3.4) | 1 | 0.7% (0.0–3.8) |
| '2'/2 | 3 | 2.7% (0.6–7.9) | 9 | 6.3% (2.9–11.5) |
| '2'/3 | 8 | 7.4% (3.3–14.1) | 28 | 19.4% (13.3–26.9) |
| '3'/3 | 8 | 7.4% (3.3–14.1) | 22 | 15.3% (9.8–22.2) |
| '3'/4 | 0 | 0% (0.0–3.4) | 2 | 1.4% (0.2–4.9) |
| '4'/4 | 0 | 0% (0.0–3.4) | 1 | 0.7% (0.0–3.8) |

a) Caucasian population has been reported by Guillmette et al., Pharmacogenetics (2000).

---

UGT1A7 Gene and Irinotecan Toxicity
UGT1A7 is also expressed in the lung,\(^{16}\) we are planning to investigate the association with lung cancer.

Inter-individual variations in cancer chemotherapy are often due to genetic alterations in drug-metabolizing enzymes, for example, thiopurine S-methyltransferase and dihydropyrimidine dehydrogenase.\(^ {26–28}\) This study, however, did not suggest any potential clinical utility of the determination of the UGT1A7 genotypes for predicting severe toxicity by irinotecan, and we found no difference in the genotype distribution between Japanese cancer patients and healthy subjects.

ACKNOWLEDGMENTS

We thank the following for their participation: Dr. Hideo Saka (Nagoya National Hospital), Dr. Toshiyuki Sawa (Gifu Municipal Hospital), Dr. Kei Muro (National Cancer Center Hospital), Dr. Hiroshi Ueoka (Okayama University Medical School), Dr. Akira Yokoyama (Niigata Cancer Center Hospital), Dr. Soh Saitoh (Aomori Prefectural Central Hospital), Dr. Hiroshi Saito (Aichi Hospital), Dr. Kiyoshi Morii (Tochigi Cancer Center), Drs. Takefumi Komiya and Gyo Asai (Kinki University), Dr. Nagio Takigawa (National Shikoku Cancer Center), and Dr. Naohiko Kuno (Japanese Red Cross Nagoya First Hospital). We also thank Hiroko Kako and Yumie Narita for their technical assistance and Drs. Toshimichi Yamamoto, Koji Kikihata and Hidehiko Saito for their statistical advice or critical review of the manuscript. This work was supported by Grants from the Ministry of Health, Labour and Welfare, Japan and the Ministry of Education, Culture, Sports, Science and Technology, Japan.

(Received October 29, 2001/Revised March 12, 2002/Accepted March 14, 2002)

REFERENCES

1) Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P. and Jacques, C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. \textit{Lancet}, \textbf{352}, 1407–1412 (1998).

2) Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsu, K., Takifi, N., Kudoh, S., Nii, H. and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. \textit{J. Natl. Cancer Inst.}, \textbf{83}, 1164–1168 (1991).

3) Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. \textit{Cancer Res.}, \textbf{51}, 4187–4191 (1991).

4) Kaneda, N. and Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. \textit{Cancer Res.}, \textbf{50}, 1721–1725 (1990).

5) Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T. and Kamataki, T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. \textit{Cancer Res.}, \textbf{56}, 3752–3757 (1996).

6) Gupta, E., Lestangi, T. M., Mick, R., Ramirez, J., Vokes, E. E. and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. \textit{Cancer Res.}, \textbf{54}, 3723–3725 (1994).

7) Iyer, L., Janisch, L., Das, S., Ramirez, J., Hurley-Buterman, C. E., DeMaria, M. M., Vokes, E. E., Kindler, H. L. and Ratain, M. J. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11). \textit{Proc. Am. Soc. Clin. Oncol.}, \textbf{19}, 690 (2000).

8) Ando, Y., Saka, H., Asai, G., Suguri, S., Shimokata, K. and Kamataki, T. \textit{UGT1A1} genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. \textit{Ann. Oncol.}, \textbf{9}, 845–847 (1998).

9) Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K. and Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. \textit{Cancer Res.}, \textbf{60}, 6921–6926 (2000).

10) Ciotti, M., Basu, N., Brangi, M. and Owens, I. S. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the \textit{UGT1} locus. \textit{Biochem. Biophys. Res. Commun.}, \textbf{200}, 199–202 (1999).

11) Strassburg, C. P., Oldhafer, K., Manns, M. P. and Tukey, R. H. Differential expression of the \textit{UGT1A} locus in human liver, biliary, and gastric tissue: identification of \textit{UGT1A7} and \textit{UGT1A10} transcripts in extrahepatic tissue. \textit{Mol. Pharmacol.}, \textbf{52}, 212–220 (1997).

12) Grams, B., Harms, A., Braun, S., Strassburg, C. P., Manns, M. P. and Obermayer-Straub, P. Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. \textit{Arch. Biochem. Biophys.}, \textbf{377}, 255–265 (2000).

13) Kuhn, J. G. Pharmacology of irinotecan. \textit{Oncology}, \textbf{12} (Suppl. 6), 39–42 (1998).

14) Gupta, E., Mick, R., Ramirez, J., Wang, X., Lesrihi, T. M., Vokes, E. E. and Ratain, M. J. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. \textit{J. Clin. Oncol.}, \textbf{15}, 1502–1510 (1997).

15) Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M. and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. \textit{Jpn. J. Cancer Res.}, \textbf{84}, 697–702 (1993).

16) Guillemette, C., Ritter, J. K., Auyeung, D. J., Kessler, F. K.,
and Housman, D. E. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. *Pharmacogenetics*, 10, 629–644 (2000).
17) Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. *Jpn. Soc. Cancer Ther.*, 28, 101–130 (1993).
18) Woolley, A. T., Guillemette, C., Li Cheung, C., Housman, D. E. and Lieber, C. M. Direct haplotyping of kilobase-size DNA using carbon nanotube probes. *Nat. Biotechnol.*, 18, 760–763 (2000).
19) McLemore, T. L., Adelberg, S., Liu, M. C., McMahon, N. A., Yu, S. J., Hubbard, W. C., Czerwinski, M., Wood, T. G., Storeng, R., Lubet, R. A., Eggleton, J. C., Boyd, M. R. and Hines, R. N. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. *J. Natl. Cancer Inst.*, 82, 1333–1339 (1990).
20) Crespi, C. L., Penman, B. W., Gelboin, H. V. and Gonzalez, F. J. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. *Carcinogenesis*, 12, 1197–1201 (1991).
21) Nakachi, K., Imai, K., Hayashi, S. and Kawajiri, K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. *Cancer Res.*, 53, 2994–2999 (1993).
22) Dutton, G. J. “Glucuronidation of Drugs and Other Compounds” (1980). CRC Press, Boca Raton, FL.
23) Hu, Z. and Wells, P. G. *In vitro and in vivo* biotransformation and covalent binding of benzo(α)pyrene in Gunn and RHA rats with a genetic deficiency in bilirubin uridine diphosphate-glucuronosyltransferase. *J. Pharmacol. Exp. Ther.*, 263, 334–342 (1992).
24) Vogel, A., Kneip, S., Barut, A., Ehmer, U., Tukey, R. H., Manns, M. P. and Strassburg, C. P. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. *Gastroenterology*, 121, 1136–1144 (2001).
25) Zheng, Z., Park, J. Y., Guillemette, C., Schantz, S. P. and Lazarus, P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. *J. Natl. Cancer Inst.*, 93, 1411–1418 (2001).
26) Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J. and Fernandez-Salgueiro, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. *J. Clin. Invest.*, 98, 610–615 (1996).
27) Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlung, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C. H. and Evans, W. E. Mercaptourine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. *J. Natl. Cancer Inst.*, 91, 2001–2008 (1999).
28) Ando, M., Ando, Y., Hasegawa, Y., Sekido, Y., Shimokata, K. and Horibe, K. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia. *Pharmacogenetics*, 11, 269–273 (2001).